Please ensure Javascript is enabled for purposes of website accessibility

Why Lexicon Pharmaceuticals Stock Doubled and Then Some on Thursday

By Eric Volkman - Updated Jan 14, 2021 at 6:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA delivered a powerful shot of good news to the company.

What happened

Now this is a stock pop. On Thursday, shares of Lexicon Pharmaceutials (LXRX 3.89%) jumped 105% (no, that's not a typo) after the company issued a major positive regulatory update.

So what

The happy news is that Lexicon's clinical-stage protein inhibitor sotagliflozin performed well enough in phase 3 clinical trials to support a New Drug Application (NDA) from the Food and Drug Administration. This paves the way for sotagliflozin to win approval for treating patients at risk of heart failure.

The company said that this "clears a key hurdle for partnership discussions around sotagliflozin ... and enables a potential NDA filing in 2021." It did not name any potential partners.

A medical professional using a microscope.

Image source: Getty Images.

Previously, Lexicon had partnered with global pharmaceutical industry giant Sanofi (SNY 1.81%) on developing sotagliflozin to combat diabetes. Disappointing clinical results prompted Sanofi to terminate the collaboration in 2019.

Lexicon had received a $300 million up-front payment in that deal, but could have picked up $1.4 billion in milestone payments if the drug had advanced further as a diabetes treatment. Sanofi paid the company $260 million to exit their arrangement.

Now what

Following the Sanofi divorce, Lexicon has been a biotech in urgent need of good news, and on Thursday it received a huge dose of it. Heart disease is the leading cause of death in the U.S., and heart failure is one of the disease's more common complications. Sotagliflozin, then, will have significant potential in the now-likely case that it comes to market.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Lexicon Pharmaceuticals, Inc. Stock Quote
Lexicon Pharmaceuticals, Inc.
LXRX
$1.74 (3.89%) $0.07
Sanofi Stock Quote
Sanofi
SNY
$54.02 (1.81%) $0.96

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
331%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.